Zacks: Analysts Expect Cyclacel Pharmaceuticals Inc (CYCC) to Announce -$0.17 EPS

Wall Street brokerages predict that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will post earnings per share of ($0.17) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Cyclacel Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.15). Cyclacel Pharmaceuticals reported earnings of ($0.91) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 81.3%. The business is expected to announce its next quarterly earnings report after the market closes on Monday, November 12th.

According to Zacks, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.63) to ($0.55). For the next financial year, analysts expect that the business will report earnings of ($0.68) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04).

A number of analysts have weighed in on CYCC shares. Zacks Investment Research upgraded Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. ValuEngine upgraded Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Roth Capital set a $8.00 price target on Cyclacel Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 4th. LADENBURG THALM/SH SH started coverage on Cyclacel Pharmaceuticals in a research note on Friday, September 7th. They issued a “buy” rating and a $6.25 price target on the stock. Finally, HC Wainwright set a $7.00 price target on Cyclacel Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Cyclacel Pharmaceuticals currently has an average rating of “Buy” and an average price target of $5.75.

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC raised its holdings in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,400 shares of the biotechnology company’s stock after buying an additional 76,500 shares during the period. Renaissance Technologies LLC owned about 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent SEC filing. 5.61% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ CYCC opened at $1.25 on Wednesday. Cyclacel Pharmaceuticals has a 12-month low of $1.14 and a 12-month high of $2.25.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Recommended Story: Trading Penny Stocks

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply